Abbott, the largest US supplier of powdered infant formula, including Similac, on Monday agreed with the FDA on the steps needed to resume production at the plant.
“I think we’re on track to have it open within a week to two weeks, most likely the outer limit of two weeks,” Mr Califf told lawmakers during a hearing of the subcommittee on human rights. United States House of Representatives Appropriations.
The company had launched a recall of its infant formula products and closed the factory in February following reports of serious bacterial infections in four infants, exacerbating a shortage at several manufacturers that began with supply chain problems in pandemic case.
The FDA cannot conclude whether the cases of sick babies are directly linked to the Abbott plant until its investigation is complete, Califf said.